Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,700 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
Omori S, Harada H, Mori K, Hisamatsu Y, Tsuboguchi Y, Yoshioka H, Morinaga R, Daga H, Kurata T, Takahashi T. Omori S, et al. Among authors: yoshioka h. Invest New Drugs. 2022 Feb;40(1):106-114. doi: 10.1007/s10637-021-01155-w. Epub 2021 Sep 8. Invest New Drugs. 2022. PMID: 34495421 Clinical Trial.
Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401).
Kaneda H, Okamoto I, Hayashi H, Yoshioka H, Miyazaki M, Kudoh S, Kimura T, Sugiura T, Sawa T, Takeda K, Iwamoto Y, Satouchi M, Akita K, Saito H, Goto I, Shibata K, Fukuoka M, Nakagawa K; West Japan Thoracic Oncology Group. Kaneda H, et al. Among authors: yoshioka h. J Thorac Oncol. 2010 Jan;5(1):105-9. doi: 10.1097/JTO.0b013e3181c07c6c. J Thorac Oncol. 2010. PMID: 19884859 Free article. Clinical Trial.
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M; West Japan Oncology Group. Mitsudomi T, et al. Among authors: yoshioka h. Lancet Oncol. 2010 Feb;11(2):121-8. doi: 10.1016/S1470-2045(09)70364-X. Epub 2009 Dec 18. Lancet Oncol. 2010. PMID: 20022809 Clinical Trial.
Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.
Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Miyazaki M, Tamura K, Kurata T, Fukuoka M, Nakagawa K. Okamoto I, et al. Among authors: yoshioka h. J Clin Oncol. 2010 Dec 20;28(36):5240-6. doi: 10.1200/JCO.2010.31.0326. Epub 2010 Nov 15. J Clin Oncol. 2010. PMID: 21079147 Clinical Trial.
Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan Thoracic Oncology Group Study 0402.
Kobayashi M, Matsui K, Katakami N, Takeda K, Moriyama A, Iwamoto Y, Takada M, Yoshioka H, Sueoka-Aragane N, Nakagawa K; West Japan Oncology Group. Kobayashi M, et al. Among authors: yoshioka h. Jpn J Clin Oncol. 2011 Aug;41(8):948-52. doi: 10.1093/jjco/hyr087. Epub 2011 Jun 29. Jpn J Clin Oncol. 2011. PMID: 21715363 Clinical Trial.
Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer.
Okamoto I, Yoshioka H, Takeda K, Satouchi M, Yamamoto N, Seto T, Kasahara K, Miyazaki M, Kitamura R, Ohyama A, Hokoda N, Nakayama H, Yoshihara E, Nakagawa K. Okamoto I, et al. Among authors: yoshioka h. J Thorac Oncol. 2012 Feb;7(2):427-33. doi: 10.1097/JTO.0b013e318238154d. J Thorac Oncol. 2012. PMID: 22071785 Free article. Clinical Trial.
A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.
Okishio K, Mio T, Kawahara M, Yoshioka H, Yanagihara K, Daimon T, Furuse K. Okishio K, et al. Among authors: yoshioka h. Jpn J Clin Oncol. 2012 May;42(5):387-93. doi: 10.1093/jjco/hys028. Epub 2012 Mar 19. Jpn J Clin Oncol. 2012. PMID: 22430871 Clinical Trial.
Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study.
Yoshioka H, Okamoto I, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Atagi S, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Nakanishi Y, Nakagawa K. Yoshioka H, et al. Ann Oncol. 2013 May;24(5):1326-31. doi: 10.1093/annonc/mds629. Epub 2012 Dec 30. Ann Oncol. 2013. PMID: 23277482 Free article. Clinical Trial.
1,700 results